Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Bristol-Myers Gets SEC Subpoena In Foreign Bribery Probe

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/26/2012 | 07:01pm CEST
   By Peter Loftus 
   Of  
 

Drug maker Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) said it has received a subpoena from the U.S. Securities and Exchange Commission as part of an investigation into bribery overseas.

Bristol-Myers said the subpoena received in March seeks information related to sales and marketing practices in "various countries."

The New York-based company said in a quarterly report filed Thursday with the SEC that it was cooperating with the government. A spokeswoman declined comment beyond the information in Thursday's SEC filing.

Bristol-Myers, which sells the anti-clotting drug Plavix, previously disclosed that the SEC was investigating the activities of the company's units in Germany, concerning potential violations of the U.S. Foreign Corrupt Practices Act, or FCPA.

U.S. authorities in recent years have stepped up enforcement of the FCPA, which bars U.S. companies from bribing foreign officials to obtain or retain business. Multinational drug and medical-device makers based in the U.S. have been among the targets of enforcement.

Last year, Johnson & Johnson (>> Johnson & Johnson) agreed to pay nearly $80 million to resolve allegations that it paid bribes to doctors in three European countries, as well as kickbacks to Iraq to illegally obtain business under former leader Saddam Hussein.

Other drug makers--including Pfizer Inc. (>> Pfizer Inc.), Merck & Co. (>> Merck & Co., Inc.) and Eli Lilly & Co. (>> Eli Lilly & Co.)--also have been the subjects of federal inquiries regarding the FCPA.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB COMPA
10/21 BRISTOL MYERS SQUIBB : Jimmy Smits Joins Stand Up to Cancer in New Public Servic..
10/20 BRISTOL MYERS SQUIBB : to Present New Data Advancing Research Across Serious Liv..
10/20 BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Accepts Bristol Myers S..
10/19 BRISTOL MYERS SQUIBB : Trevi Therapeutics Hires Dr. Helena Brett-Smith as Chief ..
10/19 BRISTOL MYERS SQUIBB : Stand Up To Cancer Awards Moffitt $2.67 Million to Study ..
10/19 BRISTOL MYERS SQUIBB : An Application for the Trademark "BEQSTIAT" Has Been File..
10/19 BRISTOL MYERS SQUIBB : BMY Extends Strategic Partnership with TARGET PharmaSolut..
10/18 JOHNSON & JOHNSON : Missouri appeals court throws out $72 million award in Johns..
10/17 BRISTOL MYERS SQUIBB : Hundreds of patients to have access to head and neck canc..
10/16 BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration (FDA) Accepts Bristol-M..
More news
News from SeekingAlpha
10/20 The Market Is Skeptical About Roche Ahead Of Major Trial Read-Outs
10/20 3 THINGS, OCTOBER 20, 2017 : Gilead's Big Day, Celgene's Bad News In Crohn's, Br..
10/19 Market Is Not Waiting For Tax Reform - Cramer's Mad Money (10/18/17)
10/18 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 18, 2017
10/18 Exploring AstraZeneca's Two-Prong Assault On Lung Cancer
Financials ($)
Sales 2017 20 540 M
EBIT 2017 5 540 M
Net income 2017 4 594 M
Debt 2017 237 M
Yield 2017 2,45%
P/E ratio 2017 23,23
P/E ratio 2018 21,47
EV / Sales 2017 5,15x
EV / Sales 2018 4,94x
Capitalization 106 B
Chart BRISTOL-MYERS SQUIBB COMPA
Duration : Period :
Bristol-Myers Squibb Compa Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 23
Average target price 60,7 $
Spread / Average Target -5,8%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Vicki L. Sato Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY10.66%105 644
JOHNSON & JOHNSON23.29%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116
MERCK AND COMPANY7.88%174 223